Physician profile
Veronica Navarrete
NPI 1043795313
$770.34
in general payments reported to CMS, 2019-2025
15 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $102 · 2023: $142 · 2024: $85.21 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507 · Education: $14.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.33 |
| Education | $14.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $123.81 | 2025 | Ozempic |
| Pfizer INC. | $121.58 | 2021-2023 | |
| Abbvie INC. | $97.57 | 2021-2024 | |
| Exeltis, USA INC. | $92.48 | 2022-2023 | Slynd |
| Astrazeneca Pharmaceuticals LP | $82.31 | 2025 | Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $58.20 | 2022 | |
| Hologic Sales and Service, LLC | $36.75 | 2025 | Aptima |
| Biogen, INC. | $29.25 | 2025 | Zurzuvae |
| Smith+Nephew, INC. | $22.74 | 2025 | Pico 7 |
| Scynexis, INC. | $21.28 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.12 | 2021 | |
| Astellas Pharma US INC | $17.44 | 2024 | Veozah |
| Organon LLC | $16.69 | 2022-2023 | Nexplanon |
| Exact Sciences Corporation | $15.36 | 2024 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $14.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Navarrete listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.